Profound Medical (NASDAQ:PROF) Issues Earnings Results

Profound Medical (NASDAQ:PROF) issued its quarterly earnings data on Thursday. The company reported ($0.27) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.27), Zacks reports. The business had revenue of $5.98 million during the quarter, compared to the consensus estimate of $10.53 million. Profound Medical had a negative net margin of 275.16% and a negative return on equity of 86.18%.

Here are the key takeaways from Profound Medical’s conference call:

• CAPTAIN randomized trial has completed enrollment and Profound will present 6?month safety and quality?of?life plus 90?day perioperative outcomes at EAU next week, a near?term catalyst management expects will validate TULSA versus robotic prostatectomy.
• Profound reported 78 TULSA?PRO sites at year?end with a 110?system late?stage sales pipeline and expects roughly 120 installs by end?2026, and management laid out a revenue/volume scenario they say would drive profitability.
• Reimbursement momentum — CMS raised payments for in?bore MR biopsy and TULSA kept Urology Level 7 (hospital payment cited at ~$13,479), while management says private payers are paying ~1.5–2.5x Medicare and >90% of denials are being overturned, which should support adoption and margins.
• Q4 revenue rose ~43% YoY to CAD ~$6M but gross margin declined to 67% and net loss widened to CAD $8.2M (cash CAD $59.7M), with management warning of near?term margin pressure from product mix and introductory international pricing.
• The TULSA?AI Volume Reduction module shortens BPH procedures to ~60–90 minutes and management estimates it could add ~400,000 patients to the TAM, while the Sonalleve platform and FDA strategy offer additional growth avenues.

Profound Medical Price Performance

Shares of PROF stock traded down $2.16 during trading hours on Friday, reaching $5.33. 1,940,019 shares of the company’s stock were exchanged, compared to its average volume of 224,559. Profound Medical has a 1 year low of $3.76 and a 1 year high of $8.95. The company has a market cap of $193.45 million, a P/E ratio of -3.98 and a beta of 0.62. The company’s 50 day moving average is $7.46 and its two-hundred day moving average is $6.33.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada increased its holdings in shares of Profound Medical by 3.5% during the 1st quarter. Royal Bank of Canada now owns 435,997 shares of the company’s stock worth $2,537,000 after buying an additional 14,795 shares during the last quarter. Raymond James Financial Inc. boosted its position in Profound Medical by 5.5% in the 2nd quarter. Raymond James Financial Inc. now owns 941,879 shares of the company’s stock valued at $5,557,000 after buying an additional 49,000 shares during the last quarter. Bank of America Corp DE grew its stake in Profound Medical by 14.3% during the 3rd quarter. Bank of America Corp DE now owns 200,160 shares of the company’s stock valued at $979,000 after purchasing an additional 24,974 shares in the last quarter. National Bank of Canada FI grew its stake in Profound Medical by 7.3% during the 3rd quarter. National Bank of Canada FI now owns 172,883 shares of the company’s stock valued at $845,000 after purchasing an additional 11,704 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in Profound Medical by 56.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 18,727 shares of the company’s stock worth $147,000 after purchasing an additional 6,787 shares during the last quarter. 47.86% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Profound Medical in a report on Monday, December 29th. Lake Street Capital increased their price objective on shares of Profound Medical from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Finally, Wall Street Zen raised Profound Medical from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $12.00.

Profound Medical Company Profile

Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches.

The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia.